Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00687687 | Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | PHASE2 | COMPLETED | 22 | — | — | May 1, 2008 | Dec 1, 2011 | Aug 7, 2012 | 40 | United States |
| Arm | Type | Description |
|---|---|---|
| Pacitaxel/Carboplatin/Iniparib | EXPERIMENTAL | Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy. |
| Name | Type | Description |
|---|---|---|
| paclitaxel | DRUG | Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days. |
| carboplatin | DRUG | Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days. |
| BSI-201 (Iniparib) | DRUG | BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days). |
Inclusion Criteria: * Patients must have advanced (stage III or IV), persistent or recurrent uterine carcinosarcoma with documented disease progression. Histologic confirmation of the original primary tumor is required. * All patients must have measurable disease. Measurable disease is defined as a...